Autonomix Investigates Novel Approach to Treating Pancreatic Cancer
Medical device company, Autonomix Medical, Inc. (Nasdaq: AMIX) has successfully completed an animal study evaluating the ability of targeted nerve ablation to impact tumor metastases and growth. The company’s share price rose on Friday in response to the news.
Autonomix is developing its catheter-based sensing technology to address pancreatic cancer-related pain. Current approaches, which primarily involve the use of opioids or invasive ethanol injections, can provide only limited relief and come with a high risk of side effects.
The preclinical study showed statistically significant reduction of the tumor mass growth and metastases in mice that had received human pancreatic tumor cells (Mia PaCa2) into the pancreatic head region.
Commenting on the study results, Lori Bisson, Chief Executive Officer of Autonomix, said, “The successful completion of this preclinical animal study and highly encouraging results, support the clinical literature suggesting that nerve fibers may be a pathway for cancer cell metastasis tumor growth. The results further support the concept that neural pathways are especially impactful in the pathogenesis of pancreatic cancer.
“Even with a small sample size in this preclinical study, the experimental group demonstrated statistically significant metastasis reduction. While our current proof of concept study in pancreatic cancer is strictly focused on pain reduction from the ablation of target nerves near the pancreas, additional studies will explore whether these preclinical findings translate to the clinical application of our technology. It is possible our ablation technology might slow human pancreatic cancer growth and metastasis and may be investigated in future clinical studies.”
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing technology for pancreatic cancer pain, a condition that causes debilitating pain and is without an effective solution. Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
